about
Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPAParkinson's disease--levodopa complications.Treatment of early Parkinson's disease.The initial treatment of Parkinson's disease should begin with levodopa.Pharmacological treatment of Parkinson's disease.Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine AgonistSaskatchewan movement disorders program.Influence of chronic L-DOPA treatment on immune response following allogeneic and xenogeneic graft in a rat model of Parkinson's disease.Parkinson's disease management strategies.Physiological and pathological role of alpha-synuclein in Parkinson's disease through iron mediated oxidative stress; the role of a putative iron-responsive elementLevodopa in the treatment of Parkinson's disease: an old drug still going strong.Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.Parkinson's disease without nigral degeneration: a pathological correlate of scans without evidence of dopaminergic deficit (SWEDD)?Alpha-synuclein modulates dopamine neurotransmission.Metabotropic glutamate receptors for Parkinson's disease therapy.Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus).Levodopa induces dyskinesias in normal squirrel monkeys.Evaluation of levodopa and carbidopa antioxidant activity in normal human lymphocytes in vitro: implication for oxidative stress in Parkinson's disease.Therapeutic advances in idiopathic Parkinsonism.
P2860
Q28376621-2F927FF2-3CF0-4AB2-AF62-184C03B5FAF7Q33714114-69BC7374-9F01-48A7-9591-145432B60AF8Q33714133-392D55B9-F280-49D6-9DB3-003742E5A0CFQ33737387-3D180B11-A915-43BA-B3E8-FA5B65514D0AQ34048261-1B2C91E9-F39E-4C51-ADD4-43AB00A9C64FQ34504316-7C33A075-6EDD-4768-A5F3-2A0DDD1EE00CQ35559550-D6B26C10-DD8F-4696-A976-60DDE21C9B91Q36198357-6F0046CD-F6A6-463A-97F1-83E61341533CQ36390875-1D07DC5F-0C44-4ED7-B057-10489AC63566Q37166339-55BB39DF-E159-4734-ABF1-D1CF45A4CE0AQ37790274-87A06BBB-6D4E-4FDA-95E9-FA1DC5765CBFQ38262418-0102A51D-DC70-421D-B5CF-B2CA16CB651AQ38385278-3111BC6D-F432-4060-8AA6-9E205A12B597Q38873771-6927440C-001B-49C7-97C4-FE7A67D821EAQ41818450-278599EC-4F4E-4BEA-A71C-5546408FF2EBQ43693344-F2B8CC18-F7CC-4E79-9E7F-FD9AD429C201Q43708064-15AB0E63-F238-4146-8CE2-432BAAAF20F4Q48471259-33D81864-CD46-4E71-AA97-24CB3A563020Q49115429-55023D82-AF7B-4914-96B3-809353DED2D3
P2860
description
1997 nî lūn-bûn
@nan
1997 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Is levodopa toxic to human substantia nigra?
@ast
Is levodopa toxic to human substantia nigra?
@en
Is levodopa toxic to human substantia nigra?
@nl
type
label
Is levodopa toxic to human substantia nigra?
@ast
Is levodopa toxic to human substantia nigra?
@en
Is levodopa toxic to human substantia nigra?
@nl
prefLabel
Is levodopa toxic to human substantia nigra?
@ast
Is levodopa toxic to human substantia nigra?
@en
Is levodopa toxic to human substantia nigra?
@nl
P2093
P356
P1433
P1476
Is levodopa toxic to human substantia nigra?
@en
P2093
P304
P356
10.1002/MDS.870120503
P407
P577
1997-09-01T00:00:00Z